PaxVax CVD 103-HgR single-dose live oral cholera vaccine

References

• Karlsson SL, Thomson N, Mutreja A, et al. Retrospective analysis of serotype switching of vibrio cholerae O1 in a cholera endemic region shows it is a non-random process. Plos Negl Trop Dis. 2016 Oct 5;10:e0005044.
   Web of Science ®Google Scholar
• Bhattacharya SK, Sur D, Ali M, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013;13:1050–1056.
   PubMed Web of Science ®Google Scholar
• Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet. 2015;8:10–6736.
   Google Scholar
• Qadri F, Wierzba TF, Ali M, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med. 2016 May;5(374):1723–1732.
   Google Scholar
• Mutreja A, Kim DW, Thomson NR, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature. 2011 Aug;24(477):462–465.
   Google Scholar
• Mukhopadhyay AK, Takeda Y, Balakrish NG. Cholera outbreaks in the El Tor biotype era and the impact of the new El Tor variants. Curr Top Microbiol Immunol. 2014;379:17–47. DOI:10.1007/82_2014_363.:17-47
   PubMed Web of Science ®Google Scholar
• Nair GB, Qadri F, Holmgren J, et al. Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. J Clin Microbiol. 2006;44:4211–4213.
   PubMed Web of Science ®Google Scholar
• Martinelli Filho JE, Lopes RM, Rivera IN, et al. Are natural reservoirs important for cholera surveillance? The case of an outbreak in a Brazilian estuary. Lett Appl Microbiol. 2016 Sep;63:183–188.
   PubMed Web of Science ®Google Scholar
• Weissman JB, DeWitt WE, Thompson J, et al. A case of cholera in Texas, 1973. Am J Epidemiol. 1974;100:487–498.
   PubMed Web of Science ®Google Scholar
• Blake PA, Allegra DT, Snyder JD, et al. Cholera–a possible endemic focus in the United States. N Engl J Med. 1980;302:305–309.
   PubMed Web of Science ®Google Scholar
• Ali M, Nelson AR, Lopez AL, et al. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015 Jun;4(9):e0003832.
   Google Scholar
• Mahon BE, Mintz ED, Greene KD, et al. Reported cholera in the United States, 1992-1994: a reflection of global changes in cholera epidemiology. Jama. 1996 Jul 24;276:307–312.
   PubMed Web of Science ®Google Scholar
• Newton AE, Heiman KE, Schmitz A, et al. Cholera in United States associated with epidemic in Hispaniola. Emerg Infect Dis. 2011;17:2166–2168.
   PubMed Web of Science ®Google Scholar
• Taylor DN, Rizzo J, Meza R, et al. Cholera among Americans living in Peru. Clin Infect Dis. 1996;22:1108–1109.
   PubMed Web of Science ®Google Scholar
• Eberhart-Phillips J, Besser RE, Tormey MP, et al. An outbreak of cholera from food served on an international aircraft. Epidemiol Infect. 1996;116:9–13.
   PubMed Web of Science ®Google Scholar
• Mascarello M, Deiana ML, Maurel C, et al. Cholera with severe renal failure in an Italian tourist returning from Cuba, July 2013. Euro Surveill. 2013 Aug 29;18:20572.
   PubMedGoogle Scholar
• Woodward WE. Cholera reinfection in man. J Infect Dis. 1971;123:61–66.
   PubMed Web of Science ®Google Scholar
• Levine MM, Nalin DR, Craig JP, et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg. 1979;73:3–9.
   PubMed Web of Science ®Google Scholar
• Levine MM. Immunity to cholera as evaluated in volunteers. In: Ouchterlony O, Holmgren J, editors. Cholera and related diarrheas. Basel: Karger; 1980. p. 195–203.
   Google Scholar
• Levine MM, Black RE, Clements ML, et al. Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: A review. In: Holme T, Holmgren J, Merson MH, et al., editors. Acute enteric infections in children. New prospects for treatment and prevention. Amsterdam: Elsevier/North-Holland Biomedical Press; 1981. p. 443–459.
   Google Scholar
• Levine MM, Kaper JB, Black RE, et al. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev. 1983;47:510–550.
   PubMedGoogle Scholar
• Levine MM, Black RE, Clements ML, et al. Duration of infection-derived immunity to cholera. J Infect Dis. 1981;143:818–820.
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet. 1986;ii:124–127.
   Google Scholar
• Clemens JD, Sack DA, Harris JR, et al. Field trial of cholera vaccines in Bangladesh: results from three year follow-up. Lancet. 1990;335:270–273.
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Herrington D, et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun. 1988;56:161–167.
   PubMed Web of Science ®Google Scholar
• Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural East Pakistan. I. The distribution of antibody in the control population of a cholera vaccine field-trial area and the relation of antibody titer to the pattern of endemic cholera. Bull WHO. 1968;38:327–334.
   PubMed Web of Science ®Google Scholar
• Mosley WH, Ahmad S, Benenson AS, et al. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull WHO. 1968;38:777–785.
   PubMed Web of Science ®Google Scholar
• Glass RI, Svennerholm AM, Khan MR, et al. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985;151:236–242.
   PubMed Web of Science ®Google Scholar
• Harris JB, LaRocque RC, Chowdhury F, et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis. 2008 Apr;9(2):e221.
   Google Scholar
• Chatterjee SN, Chaudhuri K. Lipopolysaccharides of Vibrio cholerae. I. Physical and chemical characterization. Biochim Biophys Acta. 2003 Oct;15(1639):65–79.
   Google Scholar
• Villeneuve S, Souchon H, Riottot MM, et al. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc Natl Acad Sci U S A. 2000 Jul 18;97:8433–8438.
   PubMed Web of Science ®Google Scholar
• Stroeher UH, Karageorgos LE, Morona R, et al. Serotype conversion in Vibrio cholerae O1. Proc Natl Acad Sci USA. 1992;89:2566–2570.
   PubMed Web of Science ®Google Scholar
• Gangarosa EJ, Sanati A, Saghari H, et al. Multiple serotypes of Vibrio cholerae isolated from a case of cholera. Evidence suggesting in-vivo mutation. Lancet. 1967 Mar;25(1):646–648.
   Google Scholar
• Clemens JD, Van Loon F, Sack DA, et al. Biotype as determinant of natural immunising effect of cholera. Lancet. 1991;337:883–884.
   PubMed Web of Science ®Google Scholar
• Mosley WH, Aziz KM, Rahman AS, et al. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh–three years of observation. Bull World Health Organ. 1973;49:381–387.
   PubMed Web of Science ®Google Scholar
• Philippines Cholera Committee. A controlled field trial of the effectiveness of monovalent classical and El Tor cholera vaccines in the Philippines. Bull World Health Organ. 1973;49:13–19.
   PubMed Web of Science ®Google Scholar
• Clements ML, Levine MM, Young CR, et al. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982;145:465–473.
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB. Live oral cholera vaccine: from principle to product. Bull Inst Pasteur. 1995;93:243–253.
   Google Scholar
• Ketley JM, Kaper JB, Herrington DA, et al. Diminished immunogenicity of a recombination- deficient derivative of Vibrio cholerae vaccine strain CVD103. Infect Immun. 1990;58:1481–1484.
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988;2:467–470.
   PubMed Web of Science ®Google Scholar
• Kaper JB, Michalski J, Ketley JM, et al. Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR. Infect Immun. 1994;62:1480–1483.
   PubMed Web of Science ®Google Scholar
• Ketley JM, Michalski J, Galen J, et al. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol Lett. 1993;111:15–21.
   PubMed Web of Science ®Google Scholar
• Stokes NR, Zhou X, Meltzer SJ, et al. Transcriptional responses of intestinal epithelial cells to infection with Vibrio cholerae. Infect Immun. 2004 Jul;72:4240–4248.
   PubMed Web of Science ®Google Scholar
• Viret JF, Dietrich G, Favre D. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine. 2004 Jun 23;22:2457–2469.
   PubMed Web of Science ®Google Scholar
• Simanjuntak CH, O’Hanley P, Punjabi NH, et al. The safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children. J Infect Dis. 1993;168:1169–1176.
   PubMed Web of Science ®Google Scholar
• Suharyono SC, Witham N, Punjabi N, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 1992;340:689–694.
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Butron B, Seas C, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun. 1993;61:3994–3997.
   PubMed Web of Science ®Google Scholar
• Lagos R, San Martin O, Wasserman SS, et al. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr Infect Dis J. 1999;18:624–630.
   PubMed Web of Science ®Google Scholar
• Cryz SJ. BERNA: a century of immunobiological innovation. Vaccine. 1999 Oct 1;17(Suppl 2):S1-5.:S1-S5.
   Google Scholar
• Herzog C. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. Travel Med Infect Dis. 2016 Jul;16:10.
   Google Scholar
• Kotloff KL, Wasserman SS, O’Donnell S, et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun. 1992;60:4430–4432.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor Inaba three months after vaccination. Infect Immun. 1999 Dec;67:6341–6345.
   PubMed Web of Science ®Google Scholar
• Cryz SJ, Levine MM, Kaper JB, et al. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine. 1990;8:577–580.
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr., Levine MM, Losonsky G, et al. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect Immun. 1992;60:3916–3917.
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Tacket CO, Wasserman SS, et al. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun. 1993;61:729–733.
   PubMed Web of Science ®Google Scholar
• Viret JF, Favre D, Wegmuller B, et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun. 1999;67:3680–3685.
   PubMed Web of Science ®Google Scholar
• Kantele A, Kantele JM, Arvilommi H, et al. Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine. 1991;9:428–431.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1992;166:837–841.
   PubMed Web of Science ®Google Scholar
• Chen WH, Cohen MB, Kirkpatrick BD, et al. Single-Dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016 Mar;21(62):1329–1335.
   Google Scholar
• Calain P, Chaine JP, Johnson E, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine. 2004 Jun;23(22):2444–2451.
   Google Scholar
• Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010 Oct 4;8:129.
   PubMed Web of Science ®Google Scholar
• Su-Arehawaratana P, Singharaj P, Taylor DN, et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis. 1992;165:1042–1048.
   PubMed Web of Science ®Google Scholar
• Lagos R, Avendano A, Horwitz I, et al. Tolerancia e inmunogenicidad de una dosis oral de la cepa de Vibrio cholerae 01, viva-atenuada, CVD 103-HgR: estudio de doble ciego en adultos Chilenos. Rev Med Chile. 1993;121:857–863.
   PubMed Web of Science ®Google Scholar
• Lagos R, Avendano A, Prado V, et al. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun. 1995;63:707–709.
   PubMed Web of Science ®Google Scholar
• Lagos R, Losonsky G, Abrego P, et al. Tolerancia, immunogenicidad, excresión y transmisión de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en niños Chilenos de 24 a 59 meses. Bol Hosp Infant Mex. 1996;53:214–220.
   Google Scholar
• Lagos R, Fasano A, Wasserman SS, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1999;180:1709–1712.
   PubMed Web of Science ®Google Scholar
• Wasserman SS, Losonsky GA, Noriega F, et al. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 1994;12:1000–1003.
   PubMed Web of Science ®Google Scholar
• Richie E, Punjabi NH, Sidharta Y, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine. 2000;18:2399–2410.
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, Von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet. 2005 Jul;2(366):44–49.
   Google Scholar
• Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990 Feb;3(335):270–273.
   Google Scholar
• Longini IM Jr., Nizam A, Ali M, et al. Controlling endemic cholera with oral vaccines. PLoS Med. 2007 Nov;27(4):e336.
   Google Scholar
• Chen WH, Greenberg RN, Pasetti MF, et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin Vaccine Immunol. 2014;21:66–73.
   PubMed Web of Science ®Google Scholar
• VAXCHORA product information. Silver Spring, MD: FDA.gov; 6 10 2016. 1-31-2017. Ref Type: Online Source Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm505866.htm
   Google Scholar
• Baik YO, Choi SK, Olveda RM, et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine. 2015;5:10.
   Google Scholar
• Patel SM, Rahman MA, Mohasin M, et al. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin Vaccine Immunol. 2012;19:842–848.
   PubMed Web of Science ®Google Scholar
• Sur D, Kanungo S, Sah B, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011;5:e1289.
   PubMed Web of Science ®Google Scholar
• Kanungo S, Paisley A, Lopez AL, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine. 2009 Nov;16(27):6887–6893.
   Google Scholar
• Saha A, Chowdhury MI, Khanam F, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine. 2011 Oct 26;29:8285–8292.
   PubMed Web of Science ®Google Scholar
• Azman AS, Parker LA, Rumunu J, et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. Lancet Glob Health. 2016;4:e856–e863.
   PubMed Web of Science ®Google Scholar
• Perry RT, Plowe CV, Koumaré B, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali. Bull Wld Hlth Org. 1998;76:63–71.
   PubMed Web of Science ®Google Scholar
• Anh DD, Lopez AL, Thiem VD, et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis. 2011 Jan;25(5):e1006.
   Google Scholar